IGFBP‐3 and TGF‐β inhibit growth in epithelial cells by stimulating type V TGF‐β receptor (TβR‐V)‐mediated tumor suppressor signaling
Authors:
Open Access
- 16 June 2021
- journal article
- research article
- Published by Wiley in FASEB BioAdvances
- Vol. 3 (9) , 709-729
Abstract
The TGF‐β type V receptor (TβR‐V) mediates growth inhibition by IGFBP‐3 and TGF‐β in epithelial cells and loss of TβR‐V expression in these cells leads to development of carcinoma. The mechanisms by which TβR‐V mediates growth inhibition (tumor suppressor) signaling remain elusive. Previous studies revealed that IGFBP‐3 and TGF‐β inhibit growth in epithelial cells by stimulating TβR‐V‐mediated IRS‐1/2‐dependent activation and cytoplasm‐to‐nucleus translocation of IGFBP‐3‐ or TGF‐β‐stimulated protein phosphatase (PPase), resulting in dephosphorylation of pRb‐related proteins (p107, p130) or pRb, and growth arrest. To define the signaling, we characterized/identified the IGFBP‐3‐ and TGF‐β‐stimulated PPases in cell lysates and nucleus fractions in Mv1Lu cells treated with IGFBP‐3 and TGF‐β, using a cell‐free assay with 32P‐labeled casein as a substrate. Both IGFBP‐3‐ and TGF‐β‐stimulated PPase activities in cell lysates are abolished when cells are co‐treated with TGF‐β/IGFBP‐3 antagonist or RAP (LRP‐1/TβR‐V antagonist). However, the IGFBP‐3‐stimulated PPase activity, but not TGF‐β‐stimulated PPase activity, is sensitive to inhibition by okadaic acid (OA). In addition, OA or PP2Ac siRNA reverses IGFBP‐3 growth inhibition, but not TGF‐β growth inhibition, in Mv1Lu and 32D cells. These suggest that IGFBP‐3‐ and TGF‐β‐stimulated PPases are identical to PP2A and PP1, respectively. By Western blot/phosphorimager/immunofluorescence‐microscopy analyses, IGFBP‐3 and TGF‐β stimulate TβR‐V‐mediated IRS‐2‐dependent activation and cytoplasm‐to‐nucleus translocation of PP2Ac and PP1c, resulting in dephosphorylation of p130/p107 and pRb, respectively, and growth arrest. Small molecule TGF‐β enhancers, which potentiate TGF‐β growth inhibition by enhancing TβR‐I–TβR‐II‐mediated canonical signaling and thus activating TβR‐V‐mediated tumor suppressor signaling cascade (TβR‐V/IRS‐2/PP1/pRb), could be used to prevent and treat carcinoma.Keywords
Funding Information
- National Institutes of Health (CA38808, AR052578)
This publication has 76 references indexed in Scilit:
- Wine, Beer, Alcohol and Polyphenols on Cardiovascular Disease and CancerNutrients, 2012
- Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative ResectionPLOS ONE, 2012
- Identification of a Novel Cell Death Receptor Mediating IGFBP-3-induced Anti-tumor Effects in Breast and Prostate CancerJournal of Biological Chemistry, 2010
- Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoterJournal of Clinical Investigation, 2010
- Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinomaMolecular Cancer, 2009
- Essential Role of TGF-β Signaling in Glucose-Induced Cell HypertrophyDevelopmental Cell, 2009
- Inhibitors of clathrin-dependent endocytosis enhance TGFβ signaling and responsesJournal of Cell Science, 2009
- Specific Activation of Mitogen-activated Protein Kinase by Transforming Growth Factor-β Receptors in Lipid Rafts Is Required for Epithelial Cell PlasticityMolecular Biology of the Cell, 2009
- TGF‐β control of cell proliferationJournal of Cellular Biochemistry, 2005
- Distinct pathways regulate transforming growth factor β1‐stimulated proto‐oncogene and extracellular matrix gene expressionJournal of Cellular Physiology, 1990